Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: Twelve-month results from the BIOLUX P-I randomized trial. J Endovascr Ther. 2015;22(1):14–21. https://doi.org/10.1177/1526602814564383.

Article  Google Scholar 

Tepe G, Gögebakan Ö, Redlich U, Tautenhahn J, Ricke J, Halloul Z, et al. Angiographic and clinical outcomes after treatment of femoro-popliteal lesions with a novel paclitaxel-matrix-coated balloon catheter. CardioVasc Interven Radiol. 2017;40(10):1535–44. https://doi.org/10.1007/s00270-017-1713-2.

Article  Google Scholar 

Schroeder H, Werner M, Meyer DR, Reimer P, Krüger K, Jaff MR, et al. Circulation. 2022;135(23):2227–36.

Article  Google Scholar 

Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first-in-human study. Cathete Cardiovasc. 2015;86(2):278–86. https://doi.org/10.1002/ccd.25900.

Article  Google Scholar 

Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: Twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136(12):1102–13. https://doi.org/10.1161/CIRCULATIONAHA.117.028893.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502. https://doi.org/10.1161/CIRCULATIONAHA.114.011004.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–38.

Article  Google Scholar 

Iida O, Soga Y, Urasawa K, Saito S, Jaff MR, Wang H, et al. Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther. 2018;25(1):109–17. https://doi.org/10.1177/1526602817745565.

Article  PubMed  Google Scholar 

Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. New England J Med. 2015;373(2):145–53. https://doi.org/10.1056/NEJMoa1406235.

CAS  Article  Google Scholar 

Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization. JACC Cardiovasc Interv. 2014;7(1):10–9. https://doi.org/10.1016/j.jcin.2013.05.022.

Article  PubMed  Google Scholar 

Thieme M, von Bilderling P, Paetzel C, Karnabatidis D, Perez Delgado J, Lichtenberg M. The 24-month results of the lutonix global SFA registry. JACC: Cardiovasc Interv. 2017. https://doi.org/10.1016/j.jcin.2017.04.041.

Article  Google Scholar 

Micari A, Cioppa A, Vadalà G, Castriota F, Liso A, Marchese A, et al. 2-Year results of paclitaxel-eluting balloons for femoropopliteal artery disease. JACC: Cardiovasc Interv. 2013;6(3):282–9. https://doi.org/10.1016/j.jcin.2013.01.128.

Article  Google Scholar 

Bausback Y, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, del Giudice C, et al. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Therapy. 2017;24(4):459–67. https://doi.org/10.1177/1526602817710770.

Article  Google Scholar 

Schmidt A, Piorkowski M, Görner H, Steiner S, Bausback Y, Scheinert S, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC: Cardiovascular Interv. 2016;9:715–24.

Google Scholar 

Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, et al. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions. J Endovasc Therapy. 2014;21(3):359–68. https://doi.org/10.1583/13-4630MR.1.

Article  Google Scholar 

Lichtenberg M, von Bilderling P, Ranft J, Niemoller K, Grell H, Briner L, et al. Treatment of femoropopliteal atherosclerotic lesions using the ranger paclitaxel-coated balloon catheter: 12-month results from an all-comers registry. J Cardiovasc Surg. 2017;59(1):45–50.

Article  Google Scholar 

Elmariah S, Ansel GM, Brodmann M, Doros G, Fuller S, Gray WA, et al. Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery — the TRANSCEND study. American Heart J Mosby. 2019;209:88–96.

Article  Google Scholar 

Steiner S, Schmidt A, Zeller T, Tepe G, Thieme M, Maiwald L, et al. COMPARE: prospective, randomized, non-inferiority trial of high- vs low-dose paclitaxel drug-coated balloons for femoropopliteal interventions. European Heart J. 2020;41(27):2541–52.

CAS  Article  Google Scholar 

Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.118.011245.

Article  PubMed  PubMed Central  Google Scholar